Anebulo Pharmaceuticals Inc

NASDAQ ANEB

Download Data

Anebulo Pharmaceuticals Inc Operating Cash Flow to Debt Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending September 20, 2024

Anebulo Pharmaceuticals Inc Operating Cash Flow to Debt Ratio 5 year CAGR is NA for the Trailing 12 Months (TTM) ending September 20, 2024. The operating cash flow to debt ratio measures the ability of a company's operating cash flow to cover its total debt obligations. It is calculated by dividing the operating cash flow by the total debt. This ratio provides insights into the company's ability to generate cash flow from its operations to service its debt. A higher ratio indicates a stronger capacity to generate operating cash flow relative to the level of debt, suggesting potential financial strength and debt servicing capability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: ANEB

Anebulo Pharmaceuticals Inc

CEO Dr. Joseph F. Lawler M.D., Ph.D.
IPO Date May 7, 2021
Location United States
Headquarters 1415 Ranch Road 620 South, Lakeway, TX, United States, 78734
Employees 2
Sector Healthcare
Industry Biotechnology
Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email